SLE T cells display more genes with increased rather than decreased expression. by Sean J. Bradley (823158)

“…<p><b>A)</b> Distribution of expression stratified at the 1.5-, 2-fold and q<0.05 CUFFDIFF2 significance levels. …”

Table5_Effects of exercise modalities on decreased blood pressure in patients with hypertension.docx by Thiago Rozales Ramis (5311217)

Image 5_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

“…</p>Results<p>In total, 15 types of decreased autoantibodies were identified, and 6 of them were constructed into a predictive model for early lung cancer, reaching a sensitivity of 76.19% and a specificity of 55.74%. …”

Sporulation is decreased in a Δ<i>mas</i> mutant. by Sarah Fremgen (102742)

ASO treatment suppresses the palbociclib-mediated induction of MEG3 and decrease in cell proliferation in A549 cells. by Traci L. Kruer (3342425)

Decreased activity of FASII favors the cold growth of the <i>ΔcshA</i> strain. by Vanessa Khemici (814639)

“…<i>fapR</i> mRNA levels were quantified by RT-qPCR using 16S rRNA as reference gene on total RNAs extracted from <i>wt</i> strain (PR01), <i>ΔcshA</i> strain (PR01-ΔcshA), and suppressor strains <i>ΔcshA/accC</i>^<i>M385V</i> (C51), <i>ΔcshA/accC</i>^<i>T183I</i> (sup30), <i>ΔcshA/accD</i>^<i>F253V</i> (sup17), <i>ΔcshA/accD</i>^<i>A164V</i> (sup16), <i>ΔcshA/birA</i>^{<i>D320F-FsX28</i>} (C58), <i>ΔcshA/birA</i>^{<i>R280stop</i>} (sup1) and <i>ΔcshA/bioY</i>^{<i>P123R-FsX1</i>} (C66), all at exponential growth phase in MH medium at 25°C. n = 5 for <i>ΔcshA</i>, <i>4 for wt</i> and 3 for all others. …”

Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey by Rujipat Wasitthankasem (732723)

Significantly decreased adhesion to host cells by the Δ<i>tad123</i> mutant (A) and time-dependent recovery (B). by Tra-My Duong-Nu (7300970)

HDM-induced chronic airway inflammatory cytokines decreased in TSLPR deficient mice. by Latifa Koussih (326043)

Bacterial intracellular survival increases <i>in vivo</i> persistence in a mouse model of urinary tract infection and decreases antibiotic efficacy. by Cristina Penaranda (433703)

SEM images of the samples (a) virgin sample (b) 0.4 wt. % <i>f-MWCNTs</i> (c) 0.5 wt. % <i>f—MWCNTs</i>. by Shaban Gul (14309526)

Subjects:

Inactivation of Rb leads to decreased expression of MEG3 and re-expression inhibits proliferation in A549 cells. by Traci L. Kruer (3342425)

Low oscillatory shar stress <i>Arf6</i> heterozygosity decreases Arf6 expression. by Venkateswara R. Gogulamudi (15447428)

Injection of pNaKtide diminishes PNx-induced decrease in miR-29b-3p expression. by Christopher A. Drummond (3845110)

Rab27A deficiency caused decreased amylase release from isolated acini. by Yanan Hou (736195)

Decreased recovery of NOD2^−/− compared to WT TCR transgenic CD8 T cells following respiratory influenza infection of mice. by Gloria H. Y. Lin (247710)

Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Decrease of cell viability and alterations of cell membrane permeability by infection with rotavirus isolates. by Carlos A. Guerrero (1264551)

Decrease in gastrin-, histidine decarboxylase-, and somatostatin mRNA due to the <i>H. pylori</i> B128 WT-infection. by Tobias Wiedemann (266622)

Decreased Variability of the 6-Minute Walk Test by Heart Rate Correction in Patients with Neuromuscular Disease by Kira P. Prahm (670305)

“…</p><p>Conclusion</p><p>A modified 6-minute walk test, by correcting walking distance with average heart rate during walking, decreases the variability among repeated 6-minute walk tests, and should be considered as an alternative outcome measure to the standard 6-minute walk test in future clinical follow-up and treatment trials.…”